Ogorek Anthony Joseph’s Quest Diagnostics DGX Stock Holding History

Ogorek Anthony Joseph’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17K	Hold	84	–	–	﹤0.01%	326
2026 Q1	$16K	Hold	84	–	–	﹤0.01%	319
2025 Q4	$14K	Buy	84 +4	+5%	+$728	﹤0.01%	328
2025 Q3	$15K	Buy	80 +6	+8%	+$1.06K	﹤0.01%	333
2025 Q2	$13K	Buy	74 +3	+4%	+$521	﹤0.01%	336
2025 Q1	$12K	Buy	+71	New	+$11.7K	﹤0.01%	335

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Ogorek Anthony Joseph's DGX Position: Q2 2026 in Review

Ogorek Anthony Joseph held its Quest Diagnostics (DGX) position steady in Q2 2026 at 84 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #326.

Ogorek Anthony Joseph first reported a position in DGX in Q1 2025 and has held it in 6 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Ogorek Anthony Joseph held 84 shares of Quest Diagnostics worth $17K as of Q2 2026.
Ogorek Anthony Joseph left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Ogorek Anthony Joseph's portfolio in Q2 2026, its #326 holding.
Ogorek Anthony Joseph first reported a position in Quest Diagnostics in Q1 2025 and has held it in 6 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Ogorek Anthony Joseph's 13F filing for Q2 2026, filed 7 Aug 2026.